Matsumura, Yasuhiro

Matsumura, Yasuhiro


Matsumura, Lab

Job title

Laboratory Head/Principal Research Scientist



Other affiliation

  • Visiting Scientist, Department of Immune Medicine, National Cancer center Research Institute
  • Research Director, RIN Institute Inc.


Research contents (Research key words)

Cancer induced blood coagulation, antibody therapeutics, ADC, Cancer stromal targeting (CAST) therapy, Thrombolysis


Place of Birth: Hitoyoshi City, Kumamoto Prefecture Japan.

  • 1975-1981

    MD student, Kumamoto University Medical School

  • 1981-1982

    Trainee, First Department of Surgery, Kumamoto University Medical School.

  • 1982-1983

    Trainee, Department of Surgery, Saiseikai Kumamoto Hospital

  • 1983-1984

    Trainee, Department of Surgery, Kyushyu Memorial Hospital

  • 1984-1988

    Postgraduate student, Department of Microbiology, Kumamoto University Medical School

  • 1988-1989

    Assistant Professor, Department of Microbiology, Kumamoto University Medical School

  • 1989-1990

    Postdoctoral Fellow, Department of Neoplastic Diseases, Mount Sinai Medical Center

  • 1990-1993

    Postdoctoral Fellow, Nuffield Department of Pathology, John Radcliffe Hospital, Oxford University

  • 1993-1994

    Senior Clinical Research Scientist, Nuffield Department of Pathology John Radcliffe Hospital, Oxford University.

  • 1994-1999

    Staff Physician, Department of Medicine, National Cancer Center Hospital.

  • 1999-2002

    Head, Department of Medicine, National Cancer Center Hospital.

  • 2002-2020

    Director, Division of Dvelopmental Therapeutics, EPOC, National Cancer Center

  • 2008-2020

    Director, Translational Research Committee, Japan Clinical Oncology Group

  • 2013-2020

    Visiting Professor,  Laboratory of  Cancer Biology, Department of Integrated Biosciences, Graduate School of Frontier Science, The University of Tokyo

  • 2014-2020

    Visiting Professor, Department of Medicine, Keio University

  • 2018-2020

    Visiting Professor, Kansai Medical School


  • 2005

    Japan  DDS  Nagai Memorial Award.

  • 2006

    Tamiya Memorial Award

  • 2016

    Thomson Reuters Citation Laureate Chemistry

  • 2019

    Kobayashi  Foundation for Cancer Research


  1. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Matsumura Y, Maeda H. Cancer Res. 46, 6387-6392 (1986)
  2. Significance of CD44 gene-products for cancer-diagnosis and disease evaluation. Matsumura Y, Tarin D. LANCET 340, 1053-1058 (1992)
  3. Phase I and Pharmacokinetic Study of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K  Annals Oncol  15, 517-525 (2004)
  4. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Yasunaga M, Manabe S, Tarin D, Matsumura Y. Bioconjug Chem. 22, 1776-83 (2011)
  5. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Yasunaga M, Manabe S, Matsumura Y. Cancer Sci. 102, 1396-1402 (2011)
  6. Cancer stromal targeting (CAST) therapy. Matsumura Y, Adv Drug Deliv Rev 64, 710-719 (2012)
  7. Discovery of an uncovered region in fibrin clots and its clinical significance. Hisada Y, Yasunaga M, Hanaoka S, Saijou S. Sugino T, Tsuji A, Saga T, Tsumoto K, Manabe S,. Kuroda J, Kuratsu J, Matsumura Y. Sci. Rep. 3, 2604 (2013)
  8. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Int. J. Cancer 137, 1457-1466 (2015)
  9. Tumor imaging by detecting fibrin clots in tumour stroma with anti-fibrin Fab fragment. Obonai T, Fuchigami H, Furuya F, Kozuka N, Yasunaga M, Matsumura Y. Sci. Rep. 6, 23613 (2016)
  10. Imaging mass spectrometry for the exquisite design of antibody-drug conjugates. Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. Sci. Rep. 6, 24954 (2016)
  11. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Matsumoto Y, Nichols JW, Toh K, Nomoto T, Cabral H, Miura Y, Christie RJ, Yamada N, Ogura T, Kano MR, Matsumura Y, Nishiyama N, Yamasoba T, Bae YH, Kataoka K., Nat. Nanotechnol. 11, 533-538 (2016)
  12. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Takashima H, Tsuji AB, Saga T, Yasunaga M, Koga Y, Kuroda JI, Yano S, Kuratsu JI, Matsumura Y. Sci. Rep. 7, 12341 (2017)
  13. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, Suardi S, Amini P, Fernandez JA, Burnier L, Quarroz C, Cara MDR, Matsumura Y, Hovinga JAK, Griffin JH, Simon H-U, Ibba-Manneschi L, Saller F, Carzavarini S, Angelillo-Scherrer A.  Blood 131, 1360-1371 (2018)
  14. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y, J Control Release 284, 49-56 (2018)
  15. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Fuchigami H, Manabe S, Yasunaga M, Matsumura Y, Sci Rep 8, 14211-14219 (2018)
  16. Topological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cells. Anzai T & Matsumura Y Biochem Biophys Res Commun 10:520:566-572 (2019)
  17. Cancer Drug Delivery Systems based on the Tumor Microenvironment. Matsumura Y and Tarin D (eds.) Springer (2020)
  18. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T,  Negishi  E, Harada M, Yoshida S, Matsumura Y J Control Release  323: 138-150:2020

Affiliation Society

  • President of the board of directors of Japan Society of Drug Delivery System
  • A board member of Japanese Cancer Association
  • A board member of Japanese Society of Clinical Oncology
  • Editorial board of Cancer Science
  • Editorial board of  Scientific Reports
  • Editorial board of World Journal of Gastroenterology
  • Director of Translational Research Committee of Japan Clinical Oncology Group